Korro Bio is a biopharmaceutical company dedicated to developing a new class of genetic medicines for both rare and prevalent diseases using a proprietary RNA editing platform. By harnessing the body's natural RNA editing processes, Korro aims to achieve precise single base edits that enhance the specificity and long-term tolerability of genetic therapies. With a focus on oligonucleotide-based approaches, the company leverages established delivery methods and regulatory pathways from approved therapies to bring innovative treatments to patients. Korro's mission is underscored by a commitment to collaboration and a culture driven by values such as kindness, integrity, and a desire to make a lasting impact on human health. Based in Cambridge, Massachusetts, Korro is building a team of exceptional individuals united by the vision of transforming genetic medicine.